Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors

Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway

(2015) Wei Xu et al.   CANCER LETTERS

Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73

(2015) Frankie Lam et al.   Oncotarget

An Inhibitor’s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States

(2014) Aude Echalier et al.   ACS Chemical Biology

Molecular Pathways: CDK4 Inhibitors for Cancer Therapy

(2014) M. A. Dickson   CLINICAL CANCER RESEARCH

Fluorescent biosensors for drug discovery new tools for old targets – Screening for inhibitors of cyclin-dependent kinases

(2014) Camille Prével et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

(2014) M. V. Ramana Reddy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer.

(2014) S. Kim et al.   MOLECULAR CANCER THERAPEUTICS

High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma

(2014) Simi Santala et al.   TUMOR BIOLOGY

Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury

(2014) Sarah M. Wilson et al.   Frontiers in Cellular Neuroscience

SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression

(2014) Anita C. Bellail et al.   Nature Communications

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling

(2014) Silvia Park et al.   Scientific Reports

Kinase Drug Discovery – What’s Next in the Field?

(2013) Philip Cohen et al.   ACS Chemical Biology

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

(2013) Chao Zhang et al.   ACS Chemical Biology

Emerging roles of Cdk8 in cell cycle control

(2013) Zsolt Szilagyi et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Fluorescent biosensors for high throughput screening of protein kinase inhibitors

(2013) Camille Prével et al.   Biotechnology Journal

A novel CyclinE/CyclinA-CDK Inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: Implications in cancer therapy

(2013) Lu Dai et al.   CANCER LETTERS

Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells

(2013) Bin Jia et al.   CANCER LETTERS

Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

(2013) A. M. Karst et al.   CANCER RESEARCH

Tumor-suppressive effects of CDK8 in endometrial cancer cells

(2013) Weiting Gu et al.   CELL CYCLE

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma

(2013) K. E. Sheppard et al.   CLINICAL CANCER RESEARCH

Targeting cyclin-dependent kinases in anti-neoplastic therapy

(2013) Céline Bruyère et al.   CURRENT OPINION IN CELL BIOLOGY

Anticancer Therapeutic Strategies Based on CDK Inhibitors

(2013) Luca Esposito et al.   CURRENT PHARMACEUTICAL DESIGN

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

ATP-noncompetitive CDK inhibitors for cancer therapy: an overview

(2013) Agnese Anna Abate et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A Chrysin Derivative Suppresses Skin Cancer Growth by Inhibiting Cyclin-dependent Kinases

(2013) Haidan Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Specific Inhibition of p25/Cdk5 Activity by the Cdk5 Inhibitory Peptide Reduces Neurodegeneration In Vivo

(2013) J. R. Sundaram et al.   JOURNAL OF NEUROSCIENCE

Blockbuster dreams for Pfizer's CDK inhibitor

(2013) Malini Guha   NATURE BIOTECHNOLOGY

Inhibition of α-helix-mediated protein–protein interactions using designed molecules

(2013) Valeria Azzarito et al.   Nature Chemistry

CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome

(2013) V. J. Guen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression

(2013) Qian Liang et al.   Scientific Reports

Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features

(2012) Zhizhou Fang et al.   ACS Chemical Biology

A Defect of the INK4-Cdk4 Checkpoint and Myc Collaborate in Blastoid Mantle Cell Lymphoma–Like Lymphoma Formation in Mice

(2012) Christelle Vincent-Fabert et al.   AMERICAN JOURNAL OF PATHOLOGY

Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling

(2012) Luc Demange et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma

(2012) H Miyagaki et al.   BRITISH JOURNAL OF CANCER

CDK8 Maintains Tumor Dedifferentiation and Embryonic Stem Cell Pluripotency

(2012) A. S. Adler et al.   CANCER RESEARCH

Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients

(2012) Zachary Levacque et al.   CELL CYCLE

Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation

(2012) Z. Duan et al.   CLINICAL CANCER RESEARCH

Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection

(2012) G. Nemeth et al.   CURRENT MEDICINAL CHEMISTRY

A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors

(2012) B. O. Villoutreix et al.   CURRENT PHARMACEUTICAL DESIGN

A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

(2012) Varsha Shukla et al.   FASEB JOURNAL

Cdk1 interplays with Oct4 to repress differentiation of embryonic stem cells into trophectoderm

(2012) Lei Li et al.   FEBS LETTERS

Clinical and biological significance of Cdk10 in hepatocellular carcinoma

(2012) Xiang-yu Zhong et al.   GENE

Melanoma: from mutations to medicine

(2012) H. Tsao et al.   GENES & DEVELOPMENT

Regulation of lipogenesis by cyclin-dependent kinase 8–mediated control of SREBP-1

(2012) Xiaoping Zhao et al.   JOURNAL OF CLINICAL INVESTIGATION

Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is Required for the Phosphorylation of the C-Terminal Domain of RNA Polymerase II

(2012) S.- W. G. Cheng et al.   MOLECULAR AND CELLULAR BIOLOGY

Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.

(2012) L. M. Gelbert et al.   MOLECULAR CANCER THERAPEUTICS

p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity

(2012) L. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of a time-resolved fluorescence resonance energy transfer assay for cyclin-dependent kinase 4 and identification of its ATP-noncompetitive inhibitors

(2011) Mei-Chu Lo et al.   ANALYTICAL BIOCHEMISTRY

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

(2011) D. Mahadevan et al.   ANNALS OF ONCOLOGY

Cyclin-Dependent Kinases in Brain Development and Disease

(2011) Susan C. Su et al.   Annual Review of Cell and Developmental Biology

Phosphorylation of human DNMT1: Implication of cyclin-dependent kinases

(2011) Geneviève Lavoie et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors

(2011) Caroline Corbel et al.   Biotechnology Journal

An in silico approach for the discovery of CDK5/p25 interaction inhibitors

(2011) Bing Zhang et al.   Biotechnology Journal

Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9

(2011) Nina Berberich et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

(2011) Georg Feldmann et al.   CANCER BIOLOGY & THERAPY

Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression

(2011) Hannah Wingate et al.   CELL CYCLE

Structural dissection of cyclin dependent kinases regulation and protein recognition properties

(2011) Graziano Lolli   CELL CYCLE

Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma

(2011) Christopher Abdullah et al.   CELL CYCLE

Going out of the brain: Non-nervous system physiological and pathological functions of Cdk5

(2011) Erick Contreras-Vallejos et al.   CELLULAR SIGNALLING

Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras

(2011) J. P. Eggers et al.   CLINICAL CANCER RESEARCH

Peptides or Small Molecules? Different Approaches to Develop More Effective CDK Inhibitors

(2011) D. Cirillo et al.   CURRENT MEDICINAL CHEMISTRY

Chemical and structural lessons from recent successes in protein–protein interaction inhibition (2P2I)

(2011) Xavier Morelli et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis

(2011) F. Ali et al.   DEVELOPMENT

A Novel Mechanism for Regulating Hepatic Glycogen Synthesis Involving Serotonin and Cyclin-Dependent Kinase-5

(2011) S. J. Tudhope et al.   DIABETES

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

Copy number defects of G1-Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis

(2011) Jan J. Molenaar et al.   GENES CHROMOSOMES & CANCER

Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability

(2011) Susan C. Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The CDK inhibitors in cancer research and therapy

(2011) Jonas Cicenas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cdk1 phosphorylation of the kinetochore protein Nsk1 prevents error-prone chromosome segregation

(2011) Jun-Song Chen et al.   JOURNAL OF CELL BIOLOGY

Dysregulation of CDK8 and Cyclin C in tumorigenesis

(2011) Wu Xu et al.   Journal of Genetics and Genomics

Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma

(2011) William W. Lockwood et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine

(2011) E Walsby et al.   LEUKEMIA

Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma

(2011) Asli Nar et al.   MEDICAL ONCOLOGY

Cyclin-Dependent Kinase 16/PCTAIRE Kinase 1 Is Activated by Cyclin Y and Is Essential for Spermatogenesis

(2011) P. Mikolcevic et al.   MOLECULAR AND CELLULAR BIOLOGY

Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4

(2011) Hilmar M Warenius et al.   Molecular Cancer

Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease

(2011) Alan S. L. Wong et al.   NATURE CELL BIOLOGY

CYY-1/Cyclin Y and CDK-5 Differentially Regulate Synapse Elimination and Formation for Rewiring Neural Circuits

(2011) Mikyoung Park et al.   NEURON

A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility

(2011) W K C Leung et al.   ONCOGENE

CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells

(2011) JIAN-HUA YU et al.   ONCOLOGY REPORTS

Physiological Relevance of Cell Cycle Kinases

(2011) Marcos Malumbres   PHYSIOLOGICAL REVIEWS

A Melanoma Molecular Disease Model

(2011) Smruti J. Vidwans et al.   PLoS One

Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer and Confers Chemotherapeutic Resistance

(2011) Chunyu Zhang et al.   PLoS One

Cdk5: a multifaceted kinase in neurodegenerative diseases

(2011) Zelda H. Cheung et al.   TRENDS IN CELL BIOLOGY

Structural and Functional Analysis of Cyclin D1 Reveals p27 and Substrate Inhibitor Binding Requirements

(2010) Shu Liu et al.   ACS Chemical Biology

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma

(2010) V. V. Leshchenko et al.   BLOOD

Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma

(2010) Haruhiko Nakayama et al.   CANCER

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

(2010) Marta Puyol et al.   CANCER CELL

Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase

(2010) Priya Aggarwal et al.   CANCER CELL

Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling

(2010) Georg Feldmann et al.   CANCER RESEARCH

Two Cyclin-Dependent Kinase Pathways Are Essential for Polarized Trafficking of Presynaptic Components

(2010) Chan-Yen Ou et al.   CELL

Cooperativity ofCdk4R24CandRasin melanoma development

(2010) Rachna Chawla et al.   CELL CYCLE

Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons

(2010) A Tomashevski et al.   CELL DEATH AND DIFFERENTIATION

Cyclin-dependent kinase 9–cyclin K functions in the replication stress response

(2010) David S Yu et al.   EMBO REPORTS

Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors

(2010) Richard M Eglen et al.   Expert Opinion on Drug Discovery

Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA

(2010) S. Kaneko et al.   GENES & DEVELOPMENT

CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1

(2010) B. Bartkowiak et al.   GENES & DEVELOPMENT

Molecular mechanisms of neurodegeneration in Alzheimer's disease

(2010) L. Crews et al.   HUMAN MOLECULAR GENETICS

Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication

(2010) Maria D. Begnami et al.   HUMAN PATHOLOGY

Cdk5 Nuclear Localization Is p27-dependent in Nerve Cells

(2010) Jie Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation

(2010) Ya-Li Zheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK·Cyclin Complexes

(2010) Anett Marais et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

Cdk5 Suppresses the Neuronal Cell Cycle by Disrupting the E2F1-DP1 Complex

(2010) J. Zhang et al.   JOURNAL OF NEUROSCIENCE

Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis

(2010) Jun-Li Liu et al.   MEDICAL ONCOLOGY

AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples

(2010) Matthew S. Squires et al.   MOLECULAR CANCER THERAPEUTICS

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Driving the cell cycle with a minimal CDK control network

(2010) Damien Coudreuse et al.   NATURE

The histone variant macroH2A suppresses melanoma progression through regulation of CDK8

(2010) Avnish Kapoor et al.   NATURE

CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells

(2010) Yongkun Wei et al.   NATURE CELL BIOLOGY

Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2

(2010) Shuai Chen et al.   NATURE CELL BIOLOGY

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

(2010) L Santo et al.   ONCOGENE

No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro

(2010) D. W. Peterson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

(2010) Kamil Paruch et al.   ACS Medicinal Chemistry Letters

Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen

(2010) S. John Weroha et al.   Hormones & Cancer

Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol

(2009) Ilija Androic et al.   BMC CANCER

High cyclin B1 expression is associated with poor survival in breast cancer

(2009) K Aaltonen et al.   BRITISH JOURNAL OF CANCER

Revving the Throttle on an Oncogene: CDK8 Takes the Driver Seat

(2009) R. Firestein et al.   CANCER RESEARCH

Truncation and Optimisation of Peptide Inhibitors of Cyclin-Dependent Kinase 2-Cyclin A Through Structure-Guided Design

(2009) George Kontopidis et al.   ChemMedChem

Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy

(2009) M. Y. Zhao et al.   CLINICAL CANCER RESEARCH

Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer

(2009) C. E.S. Comstock et al.   CLINICAL CANCER RESEARCH

Cell Cycle Control of Wnt Receptor Activation

(2009) Gary Davidson et al.   DEVELOPMENTAL CELL

A Novel Class of Cyclin-dependent Kinase Inhibitors Identified by Molecular Docking Act through a Unique Mechanism

(2009) Patrick Corsino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1

(2009) Yi-Ju Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nuclear cyclin D1: An oncogenic driver in human cancer

(2009) Jong Kyong Kim et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population

(2009) Hyo Seon Choi et al.   JOURNAL OF HUMAN GENETICS

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

(2009) K. F. Byth et al.   MOLECULAR CANCER THERAPEUTICS

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

(2009) M. S. Squires et al.   MOLECULAR CANCER THERAPEUTICS

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth

(2009) L. Crombez et al.   NUCLEIC ACIDS RESEARCH

Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms

(2009) A Satyanarayana et al.   ONCOGENE

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome

(2009) E K A Millar et al.   ONCOGENE

Cyclin E deregulation is an early event in the development of breast cancer

(2008) Alexandra Shaye et al.   BREAST CANCER RESEARCH AND TREATMENT

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

(2008) Elizabeth Iorns et al.   CANCER CELL

Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion

(2008) Alan P. Brown et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression

(2008) K. S.M. Smalley et al.   CANCER RESEARCH

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

Cyclin-Dependent Kinase 3-Mediated Activating Transcription Factor 1 Phosphorylation Enhances Cell Transformation

(2008) D. Zheng et al.   CANCER RESEARCH

An Unusual Member of the Cdk Family: Cdk5

(2008) Fatema A. Dhariwala et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

ATP-Noncompetitive Inhibitors of CDK-Cyclin Complexes

(2008) Mar Orzáez et al.   ChemMedChem

Phase I Study of Flavopiridol in Combination with Paclitaxel and Carboplatin in Patients with Non–Small-Cell Lung Cancer

(2008) Saby George et al.   Clinical Lung Cancer

CDK Inhibitors: Cell Cycle Regulators and Beyond

(2008) Arnaud Besson et al.   DEVELOPMENTAL CELL

The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model

(2008) A Scholz et al.   GUT

Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients

(2008) Rong Li et al.   HUMAN PATHOLOGY

Identification ofN-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†

(2008) Paul G. Wyatt et al.   JOURNAL OF MEDICINAL CHEMISTRY

CDK targets Sae2 to control DNA-end resection and homologous recombination

(2008) Pablo Huertas et al.   NATURE

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

(2008) Ron Firestein et al.   NATURE

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

(2008) K Bettayeb et al.   ONCOGENE

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology

(2008) S WANG et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CDK inhibitors in cancer therapy: what is next?

(2007) Marcos Malumbres et al.   TRENDS IN PHARMACOLOGICAL SCIENCES